Seres Therapeutics appoints Richard Kender as Interim CEO, effective March 2

Seres Therapeutics, Inc.

Thomas DesRosier and Marella Thorell step down as co-Presidents/co-CEOs but remain EVP CLO and EVP CFO.
Kender receives $520K base salary, $250K signing bonus, and options for 200,000 shares.
Matthew Henn named President (in addition to CSO); salary increased to $505K, $230K retention bonus.
Kelly Brady promoted to EVP COO; salary $475K, $230K retention bonus, options for 75,000 shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.